Emergent BioSolutions (EBS) Misses Q3 EPS by $2.71
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.56 +3.47%
EPS Growth %: -138.7%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
OMID, SICP, SCKT, More
EPS Growth %: -138.7%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of ($0.36), $2.71 worse than the analyst estimate of $2.35. Revenue for the quarter came in at $329 million versus the consensus estimate of $486.84 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GM to offer hybrid versions of top-selling SUV models - report
- Freeport beats Q3 estimates on higher copper, gold prices
- Illinois Tool Works (ITW) Tops Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
